Protein Sciences Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?

If it the FDA authorizes Novavax's COVID-19 vaccine, the Maryland-based company would target unvaccinated Americans and people who would benefit from boosters but have avoided the Pfizer-BioNTech and Moderna vaccines because of health concerns or conspiracy theories about their dangers.

Although the U.S. commitment eventually expanded to $1.8 billion, hardly any Novavax shots have found arms due to manufacturing issues, and most of the world has moved on.

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its covid vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

After years of failure, Maryland-based Novavax aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?